HTT and Huntington disease: We next examined the requirement of UBQLN2 for the clearance of a pathological Huntingtin fragment (HTTQ103), as UBQLN2 has been described to bind to aggregates in mouse models and patients with Huntington’s disease (HD) (Doi et al., 2004, Rutherford et al., 2013).